The EMA has backed broader pediatric use of Agamree and Crysvita, lowering age thresholds for rare genetic diseases affecting muscle and bone development.
Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically ...
Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...
New AMRA research: "Adverse muscle composition is associated with all-cause mortality in CKD: a UK Biobank Imaging Study" ...
Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically shortened life expectancy due to a disruption in muscle protein regulation.
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the ...
A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative method known as TEVs-TTN, for studying the specific mechanical functions of proteins through their ...
An Oregon veteran's 16-year fight with the VA over benefits for inclusion body myositis, or IBM, is part of a growing ...
I've been blogging for a few years about misophonia, an auditory/neurological disorder that I have advocated for because I and (more importantly) one of my adult children are affected. Recently, at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results